Cart
sales@molnova.com
mTRP-2 180-188
CAS No. 219312-69-3
mTRP-2 180-188( —— )
Catalog No. M30374 CAS No. 219312-69-3
This peptide is a TRP-tyrosinase-related protein. Its immunization results in effective induction of antitumor immunity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NamemTRP-2 180-188
-
NoteResearch use only, not for human use.
-
Brief DescriptionThis peptide is a TRP-tyrosinase-related protein. Its immunization results in effective induction of antitumor immunity.
-
DescriptionThis peptide is a TRP-tyrosinase-related protein. Its immunization results in effective induction of antitumor immunity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number219312-69-3
-
Formula Weight1175.33
-
Molecular FormulaC61H78N10O14
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (42.54 mM)
-
SMILES——
-
Chemical NameSequence:{Ser}{Val}{Tyr}{Asp}{Phe}{Phe}{Val}{Trp}{Leu}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Bloom MB, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997 Feb 3;185(3):453-9.
molnova catalog
related products
-
trans-2-Butene-14-di...
3-Hexenedioic acid is a normal human unsaturated dicarboxylic acid metabolite with increased excretion in patients with Dicarboxylic aciduria caused by fatty acid metabolism disorders The urinary excretion of 3-Hexenedioic acid is increased in conditions of augmented mobilization of fatty acids or inhibited fatty acid oxidation.
-
PF-01247324
PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker (IC50: 196 nM).
-
m-PEG16-Br
m-PEG16-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
